Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer

Trial Profile

Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs CAR-T CEA therapy (Primary)
  • Indications Adenocarcinoma; Liver metastases; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 10 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
    • 05 Mar 2018 Results published in the SorrentoTherapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top